Thomas A. Baillie

Thomas A. Baillie

Auto-generated profile, based on publicly available information

Thomas A. Baillie

Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
TBThomas A. Baillie
Thomas A. Baillie

1 January 2011 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TBThomas A. Baillie
Thomas A. Baillie
ARAllan E. Rettie
Allan E. Rettie
It is now widely appreciated that drug metabolites, in addition to the parent drugs themselves, can mediate the serious adverse effects exhibited by some new therapeutic agents, and as a result, there has been heightened interest in the field of drug metabolism from researchers in academia, the pharmaceutical industry, and regulatory agencies. Much progress has been made in recent years in understanding mechanisms of toxicities caused by drug metabolites, and in understanding the numerous factors that influence individual exposure to products of drug biotransformation. This review addresses some of these factors, including the role of drug-drug interactions, reactive metabolite formation, individual susceptibility, and species differences in drug disposition caused by genetic polymorphisms in drug-metabolizing enzymes. Examples are provided of adverse reactions that are linked to drug metabolism, and the mechanisms underlying variability in toxic response are discussed. Finally, some future directions for research in this field are highlighted in the context of the discovery and development of new therapeutic agents.

19 October 2020 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
TBThomas A. Baillie
Thomas A. Baillie
Covalent inhibition of target proteins using high affinity ligands bearing weakly electrophilic warheads is being adopted increasingly as design strategy in the discovery of novel therapeutics, and...

19 August 2016 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
TBThomas A. Baillie
Thomas A. Baillie

1 June 2018 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
DSDennis A. Smith
Dennis A. Smith
THTimothy Hammond
Timothy Hammond
TBThomas A. Baillie
Thomas A. Baillie
While simple O- (ether-linked) and N-glucuronide drug conjugates generally are unreactive and considered benign from a safety perspective, the acyl glucuronides that derive from metabolism of carboxylic acid-containing xenobiotics can exhibit a degree of chemical reactivity that is dependent upon their molecular structure. As a result, concerns have arisen over the safety of acyl glucuronides as a class, several members of which have been implicated in the toxicity of their respective parent drugs. However, direct evidence in support of these claims remains sparse, and due to frequently encountered species differences in the systemic exposure to acyl glucuronides (both of parent drug and oxidized derivatives thereof), coupled with their instability in aqueous media and potential to undergo chemical rearrangement (acyl migration), qualification of these conjugates by traditional safety assessment methods can be very challenging. In this Commentary, we discuss alternative (non-acyl glucuronide) mechanisms by which carboxylic acids may cause serious adverse reactions, and propose a novel, practical approach to compare systemic exposure to acyl glucuronide metabolites in humans to that in animal species used in preclinical safety assessment based on relative estimates of the total body burden of these circulating conjugates.

27 May 2020 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
TBThomas A. Baillie
Thomas A. Baillie